WuXi Biologics (Cayman) Inc. (2269.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap117.92B
Enterprise Value111.8B
P/E Ratio31.75
PEG Ratio1.6
Price/Sales Ratio6.69
Price/Book Ratio3.27
Enterprise/Revenue6.43
Enterprise/EBITDA16.03

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin0.21
Operating Margin0.32
AD

Management Effectiveness

Return On Assets0.08
Return On Equity0.11

Income Statement

Revenue21.79B
Revenue/Share5.77
Gross Profit10.02B
EBITDA8.37B
Net Income4.91B
Diluted EPS1.16

Balance Sheet

Total Cash13.04B
Total Cash/Share3.18
Total Debt2.73B
Total Debt/Equity0.06
Current Ratio3.04
Book Value Per Share13.32

Price History

52-Week Change26.02
52-Week High58
52-Week Low28.48
Moving Average 50 Days50.49
Moving Average 200 Days39.65

Statistics

Average Volume35.39M
Shares Outstanding4.12B
% Held by Institutions0.23

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor3:1
Last Split DateNovember 16, 2020
AD